Inify Laboratories (INIFY) Q3 2026 earnings summary

Executive summary

• Q3 sales were SEK 5.2m, up 5% YoY; seasonal effects weighed on activity, while UK clinical diagnostics became operational and customer interest increased.

• Growth has levelled off; ongoing customer projects are intended to support the next growth phase, with its timing the main uncertainty.

Financial highlights

• Q3 operating income was SEK 5.238m vs SEK 4.991m; 9M income was SEK 19.168m vs SEK 15.772m.

• Q3 operating loss was SEK 20.281m vs SEK 15.164m; 9M operating loss was SEK 64.196m vs SEK 48.662m.

• Q3 net loss was SEK 19.669m vs SEK 14.645m; 9M net loss was SEK 62.979m vs SEK 47.202m.

• Q3 EBITDA loss was SEK 16.674m vs SEK 13.827m; 9M EBITDA loss was SEK 52.910m vs SEK 44.948m.

• Q3 external costs rose to SEK 9.7m from SEK 7.4m and personnel costs to SEK 11.4m from SEK 10.7m, reflecting UK establishment and expanded staffing.

Outlook and guidance

• Sales growth has levelled off; several customer projects are underway, and the main uncertainty is when the next significant growth phase will begin.

• Management expects UK hospital evaluations to progress toward procurement after successful evaluation; NHS processes involve multiple stakeholders and regional funding.